Laboratory Corp Of America Holdings LH
We take great care to ensure that the data presented and summarized in this overview for LABORATORY CORP OF AMERICA HOLDINGS is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LH
View all-
Jana Partners LLC New York, NY402KShares$103 Million7.25% of portfolio
-
Cannell & Co. New York, NY341KShares$87.5 Million2.57% of portfolio
-
Bartlett & Co. LLC223KShares$57.2 Million0.82% of portfolio
-
Atlanta Capital Management CO L L C Atlanta, GA198KShares$50.8 Million0.18% of portfolio
-
Credit Suisse Ag Zurich, V8141KShares$36.3 Million0.03% of portfolio
-
Pictet Asset Management Sa Geneva 73, V8120KShares$30.7 Million0.03% of portfolio
-
Eaton Vance Management Boston, MA66.6KShares$17.1 Million0.02% of portfolio
-
Wilbanks Smith & Thomas Asset Management LLC52.5KShares$13.5 Million0.32% of portfolio
-
Jefferies Group LLC New York, NY31.2KShares$8.02 Million0.06% of portfolio
-
Degroof Petercam Asset Management Brussels, C926.6KShares$6.83 Million0.07% of portfolio
Latest Institutional Activity in LH
Top Purchases
Top Sells
About LH
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Insider Transactions at LH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 28
2025
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
5,339
-51.84%
|
$1,329,411
$249.23 P/Share
|
Feb 28
2025
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,903
+27.48%
|
$511,293
$131.43 P/Share
|
Feb 25
2025
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,314
-37.72%
|
$329,814
$251.3 P/Share
|
Feb 24
2025
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
226
-4.74%
|
$56,500
$250.4 P/Share
|
Feb 18
2025
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,413
-41.49%
|
$347,598
$246.1 P/Share
|
Feb 18
2025
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+29.32%
|
$230,319
$163.63 P/Share
|
Feb 11
2025
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41
-1.72%
|
$10,045
$245.14 P/Share
|
Feb 11
2025
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
123
+4.9%
|
-
|
Feb 11
2025
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
55
-1.14%
|
$13,475
$245.14 P/Share
|
Feb 11
2025
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+4.0%
|
-
|
Feb 11
2025
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,226
-1.37%
|
$300,370
$245.14 P/Share
|
Feb 11
2025
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,963
+3.21%
|
-
|
Feb 11
2025
|
Adam H Schechter President & CEO |
SELL
Open market or private sale
|
Direct |
6,121
-6.61%
|
$1,493,524
$244.62 P/Share
|
Feb 11
2025
|
Lance Berberian EVP, Special Advisor, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
86
-0.51%
|
$21,070
$245.14 P/Share
|
Feb 11
2025
|
Lance Berberian EVP, Special Advisor, Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
323
+1.89%
|
-
|
Feb 11
2025
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
213
-0.64%
|
$52,185
$245.14 P/Share
|
Feb 11
2025
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
807
+2.36%
|
-
|
Feb 11
2025
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
134
-2.05%
|
$32,830
$245.14 P/Share
|
Feb 11
2025
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
473
+6.75%
|
-
|
Feb 11
2025
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
86
-2.41%
|
$21,070
$245.14 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 217K shares |
---|
Payment of exercise price or tax liability | 77.1K shares |
---|---|
Open market or private sale | 93.8K shares |